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Abstract 
Long term use of NSAIDs is linked to side effects such as gastric bleeding and myocardial 
infarction. Aims: Use of in silico methods and pharmacology to investigate the potential for NSAIDs 
diclofenac, celecoxib and naproxen to bind to nuclear receptors.  
Materials and Methods: In silico screening predicted that both diclofenac and celecoxib has 
the potential to bind to a number of different nuclear receptors; docking analysis confirmed a 
theoretical ability for diclofenac and celecoxib but not naproxen to bind to TRβ. Key Findings:  
Results from TRβ luciferase reporter assays confirmed that both diclofenac and celecoxib display TRβ 
antagonistic properties; celecoxib, IC50 3.6x10-6M, and diclofenac IC50 5.3x10-6M, comparable to the 
TRβ antagonist MLS (IC50 3.1 x 10-6M). In contrast naproxen, a cardio-sparing NSAID, lacked TRβ 
antagonist effects. In order to determine the effects of NSAIDs in whole organ in vitro, we used 
isometric wire myography to measure the changes to Triiodothyronine (T3) induced vasodilation of 
rat mesenteric arteries. Incubation of arteries in the presence of the TRβ antagonist MLS000389544 
(10-5M), as well as diclofenac (10-5M) and celecoxib (10-5M) but not naproxen significantly inhibited 
T3 induced vasodilation compared to controls. 
Significance: These results highlight the benefits of computational chemistry methods used 
to retrospectively analyse well known drugs for side effects. Using in silico and in vitro methods we 
have shown that both celecoxib and diclofenac but not naproxen exhibit off-target TRβ antagonist 
behaviour, which may be linked to their detrimental side effects.  
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1. Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDS) inhibit cyclooxygenase (COX), the enzymes 
that are responsible for prostaglandin production [1]. There are two isoforms, COX-1 which is 
constitutively expressed, and COX-2 which is inducible. NSAIDS are widely used for their analgesic, 
antipyretic and anti-inflammatory properties however despite their therapeutic effectiveness, their 
use has been widely scrutinized due to their tendency to produce side effects. Since prostaglandins 
protect the gastrointestinal tract and are important in platelet aggregation, NSAID reduction of 
prostanoid production increases the risk of gastrointestinal ulceration and bleeds. Due to the toxic 
effects of NSAIDs such as diclofenac on gastrointestinal mucosa, COX-2 selective drugs such as 
celecoxib were developed. Clinical trials revealed the side effects of both pan- and COX-1 sparing 
NSAIDs led to gastrointestinal damage and cardiovascular complications including myocardial 
infarction [2, 3].  
There are currently two conflicting models that explain the cardiovascular side effects of 
NSAIDs. The first model put forward by Cheng et al states that under normal physiological conditions 
endothelial COX-2 drives the production of prostacyclins whilst platelet COX-1 drives the production 
of thromboxanes [4]. The model predicts that a balance between pro-thrombotic and antithrombotic 
state exist under normal physiological conditions. However, when an NSAID which inhibits COX-2 in 
endothelial cells is introduced, the balance is disrupted and a pro-thrombotic state develops [4]. 
Recent evidence has emerged that provides evidence that COX-2 is not expressed in 
endothelial cells [5, 6], but is highly expressed in the renal medulla [7], indicating a need for a new 
model for what causes NSAID induced side effects to be developed. Loss or inhibition of COX-2 in 
mice and man leads to an increase in the production of endogenous eNOS inhibitor, asymmetric 
dimethyl arginine (ADMA) which suggests that specific pathways are altered by COX-2 inhibition [7].  
4 
 
While much debate about the side effects of NSAIDs has concentrated on the direct effects 
of NSAIDs on COX activity, we investigated the indirect side effects of celecoxib and diclofenac using 
computational chemistry methods. In silico modelling indicated a potential for both drugs to 
associate with thyroid hormone receptor β (TRβ), and further analysis using in vitro methods 
indicate that both celecoxib and diclofenac possess TRβ antagonistic properties. This nuclear 
receptor is of great interest, with clear relationships between hypothyroidism associated with 
increased heart muscle stiffness and an increased risk of myocardial infarction [8].  
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2. Materials and Methods 
2.1 In silico methods 
Open Virtual ToxLab .5,21 [9] was used to predict toxic potential by predicting binding 
affinities to 10 off-target nuclear receptors, 4 cytochrome p450 enzymes, a transcription factor and a 
potassium ion channel and forecast endocrine and metabolic disruption, some aspects of 
carcinogenicity and cardiotoxicity. The default values of the software for the predictions of toxic 
potentials for diclofenac and celecoxib were used as described previously [9].  
The Pharmmapper, freely available web server (http://59.78.96.61/pharmmapper), was 
used to predict potential target candidates for both drugs. The mol2 files for two molecules were 
submitted to the Pharmmapper server by using default settings and limiting the target set to human 
targets [10]. 
The shape and electrostatic similarity of the diclofenac and celecoxib to ligands of the 
thyroid hormone receptor was explored using vROCS [11, 12] and EON [13, 14] software packages. Rocs 
was used to align the three dimensional alignment of the drug conformers generated by OMEGA [15-
17] with the ligands extracted from the crystal structures of the thyroid hormone receptor beta (PDB 
entries: 1Q4X, 1NQ1 and 2J4a), followed by calculation of electrostatic similarity score (ET_combo) 
using EON.  
The ability of drugs to bind into TRβ active site was investigated using Glide (Small-molecule 
Drug Discovery Suite 2014-3: Glide, Version 6.4Schrödinger, LLC, New York, NY (2014) with Maestro 
as a graphical user interface. The protein preparation wizard was utilized to adjust charges and 
protonation states of above mentioned protein data bank entries, as well as to correct problems 
with proteins target structures. Prepared protein structures were used to build energy grids with 
enclosing boxes of default sizes centred on co-crystalized ligands.  The drug molecules, diclofenac 
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and celecoxib, were docked flexibly using XP docking protocol; ligands were minimized onto OLSA-
2005 non-bonded interaction grid, with all other parameters set to their default values.  
2.2 TRβ Reporter assays 
Human TRβ reporter assay system was purchased from INDIGO Bioscience (State College, 
PA). Assays were performed according to the manufacturer’s instructions for both agonist and 
antagonist activity. Briefly, TRβ reporter cells were dispensed into the wells of the assay plate and 
immediately dosed with L-triiodothyronine (T3), celecoxib, diclofenac and naproxen. Following 24 
hour incubation at 37oC, treatment media was discarded and the Luciferase Detection Reagent 
added. Light emission from each sample well was quantified using a plate reading luminometer. In 
order to assess TRβ antagonistic activity the protocol was adjusted; TRβ Reporter Cells were exposed 
to a sub-maximal concentration of T3 (100nM) while plating cells, prior to addition of naproxen, 
celecoxib and diclofenac to the wells.  
2.3 Myography 
 Male Wistar rats (350-450g) were housed in pairs, and killed by CO2 asphyxiation. The care 
and use of the rats were carried out in accordance with UK Home Office regulations, UK Animals 
(Scientific Procedures) Act of 1986 under PPL70/7732.  
Mesenteric arteries were removed and prepared as described previously [18]. Briefly, artery 
segments were dissected in Krebs buffer (pH 7.4, NaCl 118mM, KCl 4.7mM, MgSO4 1.2mM, KH2PO4 
1.2mM, CaCl2 2.5mM, NaHCO3 25.0mM and glucose 11.0mM), and loaded onto isometric wire 
myographs. The bath solution was continuously bubbled with 95% O2 and 5% CO2. All vessels were 
allowed to equilibrate for 30 minutes prior to being set at a 'normalised' internal circumference 
0.9.L100 estimated to be 0.9 times the circumference they would maintain if relaxed and exposed to 
100mmHg transmural pressure. This was calculated for each individual vessel on the basis of passive 
length-tension characteristics of the artery and the Laplace relationship [19]. 
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Arteries were incubated with a thyroid homrone receptor antagonist MLS000389544 (10-5M; 
MLS), 10-5M diclofenac,  10-5M celecoxib or 10-5M naproxen for 30 minutes prior to addition of 
increasing concentrations of the thromboxane A2 (TP) receptor agonist 9,11-Dideoxy-11α,9α-
epoxymethano prostaglandin F2α  (U46619; 10-9M to 10-6M). Arteries were washed four times with 
Krebs, and once tone had returned to basal levels, arteries were incubated with MLS, celecoxib and 
diclofenac for further 15 minutes. Arteries were then pre-contracted with 3x10-7M U46619; once 
plataeu was acheived, vasodilation in response to increasing concetrations of L-Triiodothyronine (10-
10 to 3x10-7M) was measured.  
2.4 Materials 
All chemicals and reagents were obtained from Sigma Aldrich unless otherwise stated. Drugs were 
dissolved in water, except for U46619, celecoxib and diclofenac which were dissolved in DMSO up to 
10-2M, and then water for further dilutions.  
 
3 Results 
3.1 In silico modelling 
Using Virtualtox screening programme, structures for diclofenac and celecoxib were 
assessed for the potential binding to a series of target protein known to be correlated with the side 
effects, and a normalized toxicity potenital was calculated (Table 1). The results suggest that both 
drugs can potentially bind all nuclear receptors, albeit with various affinities. Both drugs exhibited no 
affinity with CYP enzymes, Arylhydrocarbon (AhR), and human Ether-à-go-go-Related Gene (hERG K). 
The overall predicted toxicity potentials were 0.56 and 0.57 for diclofenac and celecoxib 
respectively. These values indicate that they have potential to induce side effects to similar extent as 
chlomazone, and bisphenol B. 
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Protein Diclofenac Celecoxib 
AR 8.62x10-6 4.14x10-6 
ERα 1.31x10-5 6.22x10-8 
ERβ 5.70x10-5 1.64x10-7 
GR 4.12x10-8 5.42x10-6 
LXR 1.79x10-7 1.58x10-7 
MR 2.47x10-6 4.21x10-8 
PPARγ 2.96x10-8 6.14x10-8 
PR 4.96x10-7 8.57x10-7 
TRα 1.80x10-7 3.59x10-6 
TRβ 1.05x10-7 3.24x10-7 
 
Table 1.  Prediction model; data shows the potential binding of celecoxib and diclofenac to 10 
nuclear receptors; Androgen Receptor (AR), Estrogen receptor α (ERα), Estrogen receptor β (ER β), 
Glucocorticoid receptor (GR), Liver X receptor (LXR), Mineralcorticoid (MR), PPARγ, Progesterone 
(PR), Thyroid hormone α receptor (TRα) and thyroid hormone receptor β (TRβ). Binding potential is 
indicated by molar concentration and ToxPot is a measure of a toxic potential, a normalized binding 
affinities in respect to series of protein models with known adverse effects. 
 
The results indicated that the initial assumption that NSAIDs may interact with nuclear 
receptors was correct and warranted further investigation. The potential targets were looked at in 
light of side effects, and as a proof of principle we have taken TRβ for further consideration. The 
predicted binding affinities of drugs to this protein were not the most favourable, but were still in 
nano molar range. A possibility that diclofenac and celecoxib could bind to this receptor was further 
investigated by using the reverse docking platform Pharmmapper. Diclofenac and celecoxib 
structures were submitted to the webserver and the ability to bind to TRβ was demonstrated as a 
list of possible protein data bank files in whose active sites these two drugs could favourably bind 
(Table 2).  
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Drug 
Pharm
a 
Model 
Num 
Feature 
Fit 
Norm 
Fit 
Num 
Hydrop
hobic 
Num 
HB 
Accept
or 
Num 
HB 
Donor 
Num 
+ve 
Num 
-ve 
Num 
Arom
atic 
Diclo 2j4a_v 6 3.20 0.533 4 1 0 0 1 0 
Diclo 1nq1_v 7 3.34 0.477 4 1 1 0 1 0 
Diclo 1nax_v 7 3.08 0.440 4 1 1 0 1 0 
Diclo 1nq2_v 7 3.01 0.429 4 1 1 0 1 0 
Diclo 1nq0_v 7 2.99 0.428 4 1 1 0 1 0 
Diclo 1r6g_v 8 3.26 0.408 5 1 1 0 1 0 
Diclo 1q4x_v 9 4.01 0.445 6 2 0 0 1 0 
Cele 1q4x_v 9 2.96 0.329 6 2 0 0 1 0 
 
Table 2. The ranked list of hit target pharmacophore models for diclofenac (Diclo) and celecoxib 
(Cele) obtained using Pharmmapper webserver. The list is sorted by fit score and filtered to show 
diclofenac and celecoxib hits for TRβ.  
Although initial analysis indicates that the celecoxib should have lower probability to bind to 
TRβ, the celecoxib has considerable shape similarity to several TRβ ligands, with highest similarity to 
ligand extracted from PDB entry 1NQ1 ([4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-acetic 
acid) with Tanimoto Combo index of 0.68 and EON_ShapeTanimoto index of 0.54 (Figure 1), and high 
similarity to T3 with Tanimoto Combo index of 0.52 and EON_ShapeTanimoto index of 0.42.  
The docking analysis was carried out using three TRβ crystal structure with three different 
ligands; diclofenac (Figure 2A) could bind to active sites of all three structures, while celecoxib 
(Figure 2B) could bind only into active site of 1Q4X PDB entry, as the ligand of this complex ([4-(3-
benzyl-4-hydroxybenzyl)-3,5-dimethylphenoxy]acetic acid is in a similar size as celecoxib (Figure 2C). 
This observation indicates that the flexibility of the protein and induced fit has to be taken into 
account.  The two NSAIDs, diclofenac and celecoxib, share similar interaction patterns with TRβ 
binding site, specifically with residues I276, A317, M313, L330, L346. Furthermore R282 and N331 
are involved in hydrogen bonding formation with carboxylic and sulphonamide groups of diclofenac 
and celecoxib respectively. On the contrary, naproxen has fewer interactions with residues due to its 
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smaller size and planar shape. Importantly, its carboxylic group forms hydrogen bonds with R300 
rather than R22 and N313, that could be one of the main reason for the absence of the antagonistic 
activity against TRβ. 
 
Figure 1. Overlay of the celecoxib (depicted with thick bonds with grey carbon-carbon bonds) and a 
ligand extracted from the PDB entry 1NQ1 entry (depicted with thin green carbon- carbon bonds). 
Hydrogen atoms are not shown for clarity. 
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Figure 2. Docking analysis using three TRβ crystal structure with three different ligands; A. 
diclofenac; B. celecoxib; C. naproxen and D. original ligand present in 1Q4X. Surface shows active 
site of PDB 1Q4X entry; ligands are represented by ball-and-stick, side-chain residues of TRβ are 
represented by cylinders. Dashed lines represent hydrogen bond interactions to amino acid residues 
in TRβ. Transparent surfaces are coloured by electrostatic charges. Side-chain residues shown are 
within 4Å of bound ligand 
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3.2 TRβ Reporter assays 
In silico data indicated a potential for celecoxib and diclofenac to bind to TRβ, although 
neither compound elicited agonist properties using the TRβ luciferase reporter assay (data not 
shown). Some reporter assays were run using an antagonist protocol, incubating reporter cells with 
100nM Triiodothyronine (T3; a TRβ agonist) and then increasing concentrations of celecoxib and 
diclofenac. Celecoxib inhibited T3 induced TRβ luciferase activity with an IC50 3.6x10-6M, and 
diclofenac IC50 5.3x10-6M (Figure 3), comparable to the TRβ antagonist MLS (IC50 3.1 x 10-6M). In 
contrast naproxen lacked any effect on T3 reporter assay (Figure 3C). 
 
Figure 3. Luciferase reporter gene assay of TRβ antagonism. Reporter cells were activated with 
100nM L-triiodothyronine (T3), and TRβ antagonist activity measured following incubation with 
increasing concentrations of A. Diclofenac, B. Celecoxib, C. Naproxen and D. MLS for 24 hours; n=6-9 
from 2-5 separate experiments. 
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3.3 Myography 
 In order to determine whether celecoxib and diclofenac antagonism of TRβ has any effect in 
a whole organ system, we performed isometric wire myography of rat mesenteric arteries. T3 
induces full vasodilation of mesenteric arteries pre-contracted with U46619 (Figure 4), which is 
significantly inhibited by pre-incubation with diclofenac (Figure 4A), celecoxib (Figure 4B) and the  
TRβ antagonist MLS (Figure 4 D); naproxen had no effect on T3 dilaiton (Figure 4C).  
 The presence of 10-5M diclofenac significantly reduced U46619 mediated contraction (Figure 
5A), in contrast to incubation with 10-5M celecoxib or 10-5M naproxen which significantly increased 
U46619 mediated contraction MLS has no effect on U46619 mediated contraction (Figure 5D). 
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Figure 4 L-Triiodothyronine (T3) induced vasodilation in the presence of NSAIDs. Arteries were 
incubated with A. 10-5M diclofenac, B. 10-5M celecoxib, C. 10-5M naproxen and D. 10-5M MLS; 
following 30 minutes arteries were pre-contracted with EC80 U46619 (3x10-7M) and dilation to T3 
determined.  Data is presented as mean ± SEM, and significance is represented as *** p=<0.001 by 
two way ANOVA and significance compared to control at each concentration by Bonferroni post hoc 
test f =p<0.05, ff =p<0.01 and fff =p<0.001. 
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Figure 5 The effects of A. 10-5M diclofenac, B. 10-5M celecoxib, C. 10-5M naproxen and D. 10-5M MLS 
on U46619 mediated contraction.  Data is presented as mean ± SEM, and significance is represented 
as *** p=<0.001 by two way ANOVA and significance compared to control at each concentration by 
Bonferroni post hoc test f =p<0.05, ff =p<0.01 and fff =p<0.001. 
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4 Discussion 
Our data is the first to demonstrate that T3 induces vasodilation of rat mesenteric arteries, 
which can be significantly reduced by the TRβ antagonist MLS. Moreover, diclofenac and celecoxib 
have the capacity to bind to and antagonise TRβ and TRα receptors.  
Thyroid hormones have been shown to act directly on rat aortic artery smooth muscle cells 
[20], rat skeletal muscle resistance arteries[21] and rat mesenteric arteries[22] to induce vasodilation in a 
short time frame, indicating a non-genomic mechanism of action[23].  Reports vary in opinion on T3 
mediated dilation, which has been shown to be  endothelium independent [22], partially endothelium 
independent [21] or endothelial cells mediated via the interaction with eNOS [23].  The diversity of 
types of responses may be linked to the size of the artery[22] and role and location of the different 
isoforms of thyroid hormone receptors[23].   There are two main thyroid hormone receptors: TRα and 
TRβ, to which T3 binds. While TRβ was not found in human umbilical vein endothelial cells (HUVECs) 
or bovine aorta endothelial cells (BAECs), TRα was found to be highly expressed in HUVECs and 
BAECs and cross-couples to the phosphoinositol 3-kinase (PI3-kinase) pathway [23]. In arterial 
endothelial cells, activation of PI3 kinase leads to eNOS activation, which results in production of NO 
and thus induces full dilation. Other members of the steroid hormone superfamily have been shown 
to cross couple with the PI3-kinase/Akt pathway, including oestrogen [24], vitamin D [25], PPARβ/δ [26] 
and glucocorticoid receptors [27], indicating that non-genomic control of steroidal receptors play an 
important role in vascular homeostasis. In contrast, studies in rat arteries indicate that T3 mediates 
dilation in endothelium denuded mesenteric arteries[22], femoral arteries[22] and skeletal muscle 
resistance arteries[21], and is not significantly reduced by inhibition with antagonists of the nitric 
oxide pathway, potassium channels, L-Type calcium channels, calcium sensing receptor, G proteins 
or protein kinases, and so the actual underlying TRβ T3 dilation remains elusive[22].  
The side effects of NSAIDs have been extensively investigated, and numerous models 
postulated to explain the direct effects of NSAIDs and link to cardiovascular complications. This study 
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has used in silico modelling to investigate whether some of the effects may also be attributed to off-
target effects with nuclear receptors. Virtualtox screening returned several potential positive 
relationships, one of which is the interaction between NSAIDs and PPARγ which has previously been 
reported [28], and others which have so far not been investigated, such as a possible interaction 
between diclofenac and celecoxib with LXR. The nuclear receptor that was initially chosen and 
studied was TRβ due to two main reasons: 1) the predicted potency of binding was similar for 
diclofenac and celecoxib (1.05x 10-7M diclofenac and 3.24x10-7M celecoxib) and 2) there are well 
established links between TRβ antagonism and cardiovascular complications.  
As proof of concept we chose the potential interaction between celecoxib and diclofenac 
with TRβ, and show for the first time that both celecoxib and diclofenac have the potential to 
directly bind to and inactivate TRβ signalling. Previous reports have indicated a link between NSAIDs 
and the lowering of serum thyroid hormone concentrations [29], although this is the first report that 
indicates a potential for diclofenac and celecoxib to interfere with the TRβ receptor at physiological 
concentrations. Alterations in thyroid hormone activity is linked to cardiac function, in particular 
hypothyroidism leads to impaired systolic and diastolic function [30], as well as increased vascular 
stiffness and endothelial dysfunction [31], symptoms often associated with NSAID usage. 
The normal physiological range of total T3 in the human plasma is between 1 to 2.9 x 10-9M, 
concentrations which did not induce vasodilation in our study. However, a prominent feature of 
prolonged hyperthyroidism on the vascular system is a reduction in peripheral resistance, which may 
be due in part to the direct activity of T3 on vascular smooth muscle cell tone.  
Further studies investigating the effects of longer term incubation of diclofenac and 
celecoxib on TRβ activity are required to fully understand whether the concentrations at which these 
drugs mediate TRβ antagonism in a meaningful way are required. In this study we used a 
concentration of 10-5M diclofenac, naproxen and celecoxib, concentrations which are regularly used 
in previously published studies [32] and which are close to the maximum concentration (Cmax) ranges 
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found in human plasma. The concentration of diclofenac  can reach  1347ng/ml in the plasma; 
diclofenac has 100% bioavailability and having a pKa 4.0 it is absorbed mostly in the stomach within 
30 minutes [33]. The pharmacokinetic parameters of celecoxib dffer to diclofenac, having a greater 
tmax of 2.4 hours and Cmax 842µg/L [34], and naproxen reaches 60µg/ml in the plasma within 1.5 to 
3 hours [35].  Not accounting for plasma binding, the equivalent molarity that is calculated for each 
NSAID would be 440µM diclofenac, 2.21µM celecoxib and 260µM naproxen in the plasma, 
concetrations a lot higher or lower than the 10µM used in this study. 
T3 mediated dilation of rat mesenteric arteries is significantly inhibited by the thyroid 
hormone antaongonist MLS, as well as NSAIDs diclofenac and celecoxib. The chemical structure of 
celecoxib and diclofenac has similarities in shape, and differ in comparison to small, flat naproxen. 
Diclofenac and celecoxib shared binding profiles with other known TRβ binding molecules, and 
exhited TRβ antagonistic behaviours in the reporter assay as well as inhibiting T3 mediated 
vasodilation. These effects were not apparent with naproxen, which lacked effect on the TRβ 
reporter assay and had no effect on T3 mediated dilation. This is the first report to show the effects 
of diclofenac and celecoxib on T3 dilation, and raises insight in the NSAID structure required to avoid 
unwanted TRb antagonism. 
MLS had no effect on U46619 mediated contraction, indicating that TRβ has no effect on TP 
receptor mediated contraction. On the other hand, diclofenac significantly reduced U46619 
mediated contraction, and the NSAIDs celexoxib and naproxen significantly increased U46619 
contraction, results which can be explained by the inhibition of contractile and dilatory prostanoids 
that contribute to U46619 contraction[36]. 
It is clear that the majority of side effects induced by long term usage of NSAIDs are due to 
the inhibition of downstream prostanoids, in particular prostacyclin. Not all of the effects can be 
attributed to direct changes to the prostanoids profile, and we demonstrate here that diclofenac and 
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celecoxib have the potential to bind to and inactivate THβ receptor. Our study indicates that on the 
short term this may have an effect on vascular homeostasis by altering the direct effects of T3 on 
vascular responses, and suggests that longer term effects akin to hypothyroidism are a potential risk 
from NSAID usage. 
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